COPDNCT03684330
Vitamin D Supplementation and WBV in Inflammatory Markers, Strength and Body Composition in Old Patients With COPD
A study testing Vitamin D and whole body vibration (WBV) in people with COPD and Aging, run by Maíra F Pessoa at 1 site in Brazil.
Trial summary
Verify the influence off vitamin D supplementation and a whole body vibration (WBV) protocol during 03 months in older patients chronic obstructive pulmonary disease Read more about this study
- Who is it for?
- Ages 60 to 75 yearsHealthy volunteers can take part
- What is being tested?
- Vitamin D and whole body vibration (WBV)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 59 participants
- Where
- 1 siteBrazil
- Study dates
- 20 May 2018to 30 Sep 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Older patients with COPD
- Both genders
- Sedentary according to International Physical Activity Questionnaire (IPAQ) short form
- BMI in between 22.9 and 28 kg/m2.
- Older patients with COPD should have a clinical-functional diagnosis of the disease according to GOLD (GOLD, 2018), have been ex-smokers and have not used corticosteroids or have used this drug in a stable way for at least one year (without dosage or medication modifications).
- Older volunteers should be self-referenced healthy or, if they had systemic arterial hypertension or diabetes mellitus, these comorbidities should be controlled by diet or regular medication use.
Who cannot join
- Older patients with COPD who had episodes of exacerbation in the last three months, those with pulmonary rehabilitation programs in the last year, those who used home oxygen therapy, and patients with COPD associated comorbidities were excluded.
- Volunteers of both groups who were taking vitamin D were excluded, as well as the current smokers, although occasional, volunteers with a history of labyrinthitis or thromboembolism, who had undergone surgical procedures of any size in the last year, such as plaques, pins or cardiac pacemakers, those with unconsolidated fractures that used medications that affected bone metabolism or lean mass, or those who had difficulties adapting to the assessment or the training protocol.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Efficacy of Vitamin D Supplementation Added to WBV Chronic Protocol in Inflammatory Markers, Peripheral and Respiratory Strength and Body Composition in Old Patients With COPD
Verify the influence off vitamin D supplementation and a whole body vibration (WBV) protocol during 03 months in older patients chronic obstructive pulmonary disease
- Being tested
- Vitamin D, whole body vibration (WBV)
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vitamin DDietary supplement
a dose once a week
whole body vibration (WBV)Other
03 months of WBV training three times per week
| Study group | Role | What they receive |
|---|---|---|
| Vitamin D supplementation | Active comparator | Not described Receives: Dietary Supplement: Vitamin D; Other: whole body vibration (WBV) |
| Vitamin D placebo | Placebo comparator | Not described Receives: Other: whole body vibration (WBV) |
What is being measured
The primary outcome is the main question the study is designed to answer.
serum inflammatory marker Interleukine-6 (IL-6)
changes in total serum values of interleukine 6
Measured: before and immediately up to 12 weeks in WBV training.
serum inflammatory marker Interleukine-8 (IL-8)
changes in total serum values of interleukine 8
Measured: before and immediately up to 12 weeks in WBV training.
serum inflammatory marker TNF-alpha ( and BDNF)
changes in total serum values of tumoral necrose factor alpha
Measured: before and immediately up to 12 weeks in WBV training.
serum inflammatory marker and brain derived neurotrophic factor (BDNF)
changes in total serum values of brain derived neurotrophic factor
Measured: before and immediately up to 12 weeks in WBV training.
Secondary outcomes (3)
Peripheral strength
Changes in Peripheral muscle strength assessed by the hand dynamometer (device that assess strength) in values obtained from the mean of 03 maneuvers of isokinetic contraction, in centimeters of water
Measured: before and immediately up to 12 weeks in WBV training.
Body composition
Changes in electrical bioimpedance assessing lean mass in segmental areas and trunk
Measured: before and immediately up to 12 weeks in WBV training.
Respiratory strength
Changes in respiratory strength obtained from a manovacuometer, collecting the major value of 03 maneuvers of the maximal inspiration (vacuometer) to the maximal expiration pressures (manometer), with values obtained in centimeters of water
Measured: before and immediately up to 12 weeks in WBV training.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2018
- Study start20 May 2018
- Primary completion30 Aug 2018
- Study completion30 Sep 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COPDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 59 participants (actual)
Sponsor and investigators
- Lead sponsor
- Maíra F Pessoa
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Maíra F Pessoa, Universidade Federal de Pernambuco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03684330
- Sponsor's protocol ID
- croninflam
- Status last verified
- Sep 2018
- First submitted
- 22 Sep 2018
- Last updated
- 25 Sep 2018
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Vitamin D Supplementation Added to WBV Chronic Protocol in Inflammatory Markers, Peripheral and Respiratory Strength and Body Composition in Old Patients With COPD
- ClinicalTrials.gov ID
- NCT03684330
- Acronym / sponsor ID
- croninflam
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 59 participants (actual)
- Lead sponsor
- Maíra F PessoaUniversity, hospital or other
- Study start
- 20 May 2018 (actual)
- Primary completion
- 30 Aug 2018 (actual)
- Study completion
- 30 Sep 2018 (estimated)
- First posted
- 25 Sep 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Verify the influence off vitamin D supplementation and a whole body vibration (WBV) protocol during 03 months in older patients chronic obstructive pulmonary disease
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Vitamin D supplementation | Active comparator | Dietary Supplement: Vitamin D, Other: whole body vibration (WBV) |
| Vitamin D placebo | Placebo comparator | Other: whole body vibration (WBV) |
Who may qualify
- Ages
- 60 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Older patients with COPD
- Both genders
- Sedentary according to International Physical Activity Questionnaire (IPAQ) short form
- BMI in between 22.9 and 28 kg/m2.
- Older patients with COPD should have a clinical-functional diagnosis of the disease according to GOLD (GOLD, 2018), have been ex-smokers and have not used corticosteroids or have used this drug in a stable way for at least one year (without dosage or medication modifications).
Key exclusion criteria (2 listed)
- Older patients with COPD who had episodes of exacerbation in the last three months, those with pulmonary rehabilitation programs in the last year, those who used home oxygen therapy, and patients with COPD associated comorbidities were excluded.
- Volunteers of both groups who were taking vitamin D were excluded, as well as the current smokers, although occasional, volunteers with a history of labyrinthitis or thromboembolism, who had undergone surgical procedures of any size in the last year, such as plaques, pins or cardiac pacemakers, those with unconsolidated fractures that used medications that affected bone metabolism or lean mass, or those who had difficulties adapting to the assessment or the training protocol.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vitamin Da dose once a week | Dietary supplement | Vitamin D supplementation |
| whole body vibration (WBV)03 months of WBV training three times per week | Other | Vitamin D placebo, Vitamin D supplementation |
Primary outcome
serum inflammatory marker Interleukine-6 (IL-6)
Time frame: before and immediately up to 12 weeks in WBV training.
changes in total serum values of interleukine 6
serum inflammatory marker Interleukine-8 (IL-8)
Time frame: before and immediately up to 12 weeks in WBV training.
changes in total serum values of interleukine 8
serum inflammatory marker TNF-alpha ( and BDNF)
Time frame: before and immediately up to 12 weeks in WBV training.
changes in total serum values of tumoral necrose factor alpha
serum inflammatory marker and brain derived neurotrophic factor (BDNF)
Time frame: before and immediately up to 12 weeks in WBV training.
changes in total serum values of brain derived neurotrophic factor
3 secondary outcomes
Peripheral strength
Time frame: before and immediately up to 12 weeks in WBV training.
Body composition
Time frame: before and immediately up to 12 weeks in WBV training.
Respiratory strength
Time frame: before and immediately up to 12 weeks in WBV training.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2018.
- Individual participant dataSharing planned: Undecided
Related trials for COPD
Recruiting
THERMotherapy Against Persistent Bacterial LUNG Infections
Lung Diseases, Obstructive, Bronchiectasis
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Active, not recruiting
Influence of FreeO2 on Percentage of Time Within Oxygen Saturation Target Using Noninvasive Ventilation (NIV) and Continuous Positive Airway Pressure (CPAP) for Patients Admitted for AECOPD or Bariatric Surgery
COPD Exacerbation, Oxygen Toxicity
Recruiting
Comparison of Several Oxygenation Targets With Different Oxygen Interfaces - Impact on Oxygen Flow Rates
Oxygen Toxicity, COPD Bronchitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vitamin D and whole body vibration (WBV) in people with COPD and Aging, run by Maíra F Pessoa at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
serum inflammatory marker Interleukine-6 (IL-6) (time frame: before and immediately up to 12 weeks in WBV training.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2018; AzTrials last refreshed its copy on 7 Nov 2026.